Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
The multiple disease domains affected in psoriatic arthritis (PsA) may make composite endpoints appropriate for assessing changes in disease activity over time. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Data from two phase 3 studies of patients with PsA were used to evaluate the effect of tofacitinib on composite endpoints.
Oral Psoriatic Arthritis triaL (OPAL) Broaden was a 12-month study of tumor necrosis factor i...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
(Version of record, pdf, 1007.5KB)
- Publisher copy:
- Copyright holder:
- Helliwell et al
- Copyright date:
- © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record